Loading...
Loading...
GLS| Name | Value |
|---|---|
| Revenues | 7.5M |
| Cost of Revenue | 4.9M |
| Gross Profit | 2.6M |
| Operating Expense | 45.7M |
| Operating I/L | -43.1M |
| Other Income/Expense | 37.5M |
| Interest Income | 0.0M |
| Pretax | -5.7M |
| Income Tax Expense | 0.4M |
| Net Income/Loss | -5.8M |
Gelesis Holdings Inc. is a commercial stage biotherapeutics company specializing in developing biomimicry treatments for obesity and GI-related chronic diseases. The company's flagship product, PLENITY, is an orally administered, non-stimulant, and non-systemic aid for weight management. Gelesis also offers a pipeline of potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation.
